Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current clinical practice where intensive cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based on the onco-hematologist criteria). The primary endpoint is to determine whether this primary prevention englobing cardiovascular monitoring plus intensive multidisciplinary management is superior to the current clinical practice in reducing all cause mortality. Other secondary objectives of the study are to analyze the impact of this intensive cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological mortality, hospitalization and/or urgent care due to cardiovascular complications, hospitalization and/or urgent oncological care due to cancer complications, tumor progression and cost-effectiveness analysis. A total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing standardized anti-tumoral treatment, will be recruited. The incidence of primary and secondary outcomes will be measured at 2 and 5 years
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 65 lat
- •Oczekiwana długość życia dłuższa niż 1 rok
- •Rozpoznanie raka okrężnicy, raka piersi, chłoniaka lub białaczki limfocytowej
- •Podpisana świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Uczestnictwo w innym badaniu klinicznym kolidującym z tym protokołem
- •Wcześniejsze leczenie przeciwnowotworowe potencjalnie szkodliwe dla serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 65 Years
- Last updated (source)
- March 21, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (14)
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Hospital de Galdakao-Usansolo
Galdakao, Spain
Hospital Universitario Vall d´Hebron
Barcelona, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Universitario de La Princesa
Madrid, Spain
Hospital G. Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Hospital Universitario Río Hortega
Valladolid, Spain
Trial contact
Pedro L Sánchez, Ph. D.
Ana Martín-García, Ph. D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.